Journal article
Methylene blue treatment for residual symptoms of bipolar disorder: Randomised crossover study
Abstract
BACKGROUND: Residual symptoms and cognitive impairment are among important sources of disability in patients with bipolar disorder. Methylene blue could improve such symptoms because of its potential neuroprotective effects.
AIMS: We conducted a double-blind crossover study of a low dose (15 mg, 'placebo') and an active dose (195 mg) of methylene blue in patients with bipolar disorder treated with lamotrigine.
Authors
Alda M; McKinnon M; Blagdon R; Garnham J; MacLellan S; O'Donovan C; Hajek T; Nair C; Dursun S; MacQueen G
Journal
The British Journal of Psychiatry, Vol. 210, No. 1, pp. 54–60
Publisher
Royal College of Psychiatrists
Publication Date
1 2017
DOI
10.1192/bjp.bp.115.173930
ISSN
0007-1250